The vaccine manufacturer Biontech made a net profit of 10.3 billion euros last year.
Sales were almost 19 billion euros, as the Mainz-based company announced on Wednesday.
In view of the demand for the company's corona vaccine, it has almost tripled its previous year's profit of 15.2 million euros.
Sales in the previous year were 482 million euros.
Biontech has now confirmed the sales forecast for the corona vaccine of 13 to 17 billion euros this year.
Shares listed in the US rose more than 5 percent.
Biontech announced that it intends to distribute part of the record profit to its shareholders.
The board of directors intends to approve a share buyback program of up to $1.5 billion over the next two years and to propose a special dividend of €2 per share.
Study of new Omicron vaccine underway
Last year, 2.6 billion corona vaccine doses were delivered, 100 million more than expected.
Research and development spending is expected to increase by around 50 percent this year compared to 2021, to between EUR 1.4 billion and EUR 1.5 billion.
According to the company, it expects to publish the first data from the clinical study on the safety, tolerability and effectiveness of a vaccine tailored to the omicron variant in April.
This data is intended to support potential regulatory submissions.
Around 2150 adults are taking part in the study.
The current Covid-19 vaccine and an omicron-based vaccine are being investigated in both test persons who have already been vaccinated and those who have not been vaccinated so far.
According to Biontech, the study was expanded to include various combination approaches.
Other vaccine candidates are also to be tested.